Preferred Label : Vobramitamab Duocarmazine;
NCIt synonyms : Anti-B7H3 ADC; Anti-B7H3 Antibody-drug Conjugate MGC018;
NCIt definition : An antibody-drug conjugate (ADC) comprised of vobamitamab, an anti-B7-homolog 3 (B7-H3,
CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody, conjugated to
the cleavable linker-duocarmycin payload duocarmazine (valine-citrulline-seco duocarmycin
hydroxybenzamide azaindole; vc-seco-DUBA), with potential antineoplastic activity.
Upon administration of vobramitamab duocarmazine, vobramitamab specifically targets
and binds to the cell surface antigen B7-H3, leading to internalization of the ADC
by B7-H3-expressing tumor cells. The vc linker is cleaved inside the tumor cell by
proteases, thereby releasing the duocarmycin payload. Duocarmycin binds to the minor
groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3,
a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily,
is overexpressed on certain tumor cell types and on various immune cells but is minimally
expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation
and its overexpression plays a key role in immuno-evasion, tumor cell invasion and
metastasis, and its expression is correlated with poor prognosis.;
UNII : 2ZK3D69DQJ;
CAS number : 2490556-51-7;
Molecule name : MG-C018; MGC 018;
NCI Metathesaurus CUI : CL951453;
Origin ID : C159495;
UMLS CUI : C5706650;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
